July 17 (Reuters) - Merck has beaten back an appeal by nearly 1,200 plaintiffs who claimed their cases were improperly dismissed by the federal judge overseeing mass torts litigation over its Zostavax shingles vaccine.
Novo owner backs Swiss biotech Asceneuron in $100 million round
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Eyebiotech Limited (EyeBio). EyeBio is now a wholly-owned subsidiary of Merck.
Merck Animal Health Completes Acquisition of Elanco’s Aqua Business
After a drawn-out litigation process, Merck & Co. seems to have finally washed its hands of more than a thousand lawsuits tied to its shingles vaccine Zostavax.
Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer
Roche to halt trial in latest setback for lung cancer immunotherapy
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
N-Power Medicine Collaborates with Merck to Expand Oncologist and Patient Access to Clinical Trials